You may have heard the "ARRIVE trial" mentioned by your provider, in a birth class, or scrolling through pregnancy forums, usually attached to the idea that induction at 39 weeks is just as safe, maybe safer. The trial is real, and it changed a lot of clinical practice. But the one-line summary leaves out some context worth understanding before it factors into your own decisions.
What the trial actually did
Published in the New England Journal of Medicine in 2018, the ARRIVE trial (A Randomized Trial of Induction Versus Expectant Management) enrolled just over 6,100 low-risk, first-time (nulliparous) pregnant people carrying a single, head-down baby, with a confirmed due date. At 38 weeks, participants were randomly assigned to one of two groups: induction at 39 weeks 0 to 4 days, or expectant management, meaning they waited for labor to start on its own, with induction offered later only if a medical reason came up.
What it found
Two outcomes were tracked. The primary outcome was a combined measure of serious newborn complications and perinatal death. The secondary outcome was the rate of cesarean birth.
- Primary outcome: 4.3% of babies in the induction group had a serious complication or died, compared to 5.4% in the expectant management group. This looks like a meaningful difference, but statistically it landed right at the edge of significance, the kind of result researchers describe as inconclusive rather than a clear win.
- Secondary outcome: Cesarean birth was less common in the induction group, 18.6%, compared to 22.2% in the expectant management group. This difference was statistically significant, and it's the finding that got most of the attention.
The nuance that often gets lost
Quick summaries tend to compress the study's actual conclusion, that induction did not significantly lower the newborn complication rate but did significantly lower the cesarean rate, into a simpler "induction is safer." That's not quite what the data showed. The clearest, most statistically solid finding was the drop in cesarean rate. The newborn safety numbers were close enough that the trial couldn't confidently say one approach was safer than the other on that measure, only that induction didn't appear to make things worse.
Who the results actually apply to
The eligibility criteria matter as much as the results. Every participant was:
- Pregnant for the first time
- Carrying one baby, positioned head-down
- Confirmed at 38 weeks 0 days to 38 weeks 6 days by reliable dating
- Considered low-risk, with no medical complications requiring earlier delivery
If any of those don't describe your pregnancy, the ARRIVE findings don't directly apply. This is a common way research findings get generalized further than the data actually supports.
How ACOG responded
In response to the trial, ACOG and the Society for Maternal-Fetal Medicine issued a joint statement calling it reasonable for providers to offer elective induction at 39 weeks to eligible low-risk, first-time mothers, not a recommendation that everyone in that category should be induced. Their guidance specifically calls for shared decision-making: a conversation about the tradeoffs, not a default protocol.
What this means for you
If your provider brings up the ARRIVE trial as a reason for induction, it's a reasonable thing to have researched, and a reasonable option to consider. It's also worth asking whether your own situation matches the study's population, and whether the recommendation is about your specific pregnancy or a general policy. Both induction at 39 weeks and waiting for labor to start on its own are supported by the evidence for eligible, low-risk pregnancies. Which one is right for you is a conversation, not a formula.
This post is for educational purposes only. Talk with your care provider about what's appropriate for your specific pregnancy.